Compare FRSH & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSH | ARQT |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2021 | 2020 |
| Metric | FRSH | ARQT |
|---|---|---|
| Price | $12.85 | $31.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | $19.44 | ★ $24.83 |
| AVG Volume (30 Days) | ★ 4.2M | 2.4M |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $810,640,000.00 | $317,929,000.00 |
| Revenue This Year | $18.20 | $85.51 |
| Revenue Next Year | $13.36 | $30.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.18 | ★ 129.21 |
| 52 Week Low | $10.51 | $11.13 |
| 52 Week High | $19.77 | $31.45 |
| Indicator | FRSH | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 68.09 | 69.89 |
| Support Level | $11.77 | $28.95 |
| Resistance Level | $12.43 | $31.27 |
| Average True Range (ATR) | 0.41 | 1.48 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 89.80 | 93.97 |
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.